Infection prevention
the correct place after you have overtaken. We need to teach our staff how to use guidelines appropriately, not just get the correct content in place,” she asserted. Finally, she emphasised the importance of
psychological safety.: “This is a core element of patient safety – we need to ensure that infection prevention and control professionals and broader healthcare workers feel safe to express ideas and concerns openly,” Rose Gallagher emphasised. “We all have questions and we should all feel comfortable to ask those. We need to be comfortable and learn to recognise our mistakes and challenge professionally without fear of consequences,” she commented. In her closing comments, she cited the words
of Sir Ian Kennedy, who wrote the foreword to the investigation report into the outbreak at Stoke Mandeville Hospital. “He reminds us that an awful tragedy took place between 2003 and 2004 at Stoke Mandeville. There’s an absolute need to place the safety of patients – and I would say healthcare workers – at the forefront of the agenda of healthcare; safety can never be allowed to play ‘second fiddle’ to other objectives that may emerge from time to time,” she concluded.
Driving improvement in diagnostics Prof. Mark Wilcox, National Clinical Director for Infection Prevention and Control & AMR Diagnostics, NHS England, went on to discuss the scientific and system-level challenges needed to improve infection outcomes. Drawing on the AMR National Action Plan (2024-29), he addressed the challenges, and potential solutions to improve infection management. He highlighted the findings of the first
comprehensive analysis of the global impact of AMR, which estimated resistance caused around 1.27 million deaths in 2019 – more deaths than HIV/AIDS or malaria. The 2023 Point Prevalence Survey on HCAIs in England (including 121 NHS Trusts and independent sector organisations) also found that ~1 in 13 patients (7.6%) had at least one HCAI.
He explained that the UK AMR National Action
Plan (2024-2029), first published in May 2024, contains outcomes and commitments that aim to make progress towards the UK’s 20-year vision – for AMR to be contained, controlled and mitigated by 2040. It has nine strategic outcomes organised under four themes – outlining action to be taken across the sectors of human health, agriculture and the environment. “There are potentially over 500 deliverables
across various parts of government – not just the Department of Health and Social
care,” commented Prof. Wilcox. He reported that he had been working with colleagues on “a reset” of the action plan. The team have identified 153 potential interventions from an infection perspective that are being ranked in terms of priority, so that efforts can become more focused – particularly in light of current reorganisation in healthcare. Some of the UK AMR National Action Plan
targets include: 1. By 2029, we aim to prevent any increase in a specified set of drug-resistant infections in human from the 2019 baseline.
2. By 2029, we aim to prevent any increase in Gram-negative bloodstream infections in humans from the 2019 to 2020 financial year baseline.
3. By 2029, we aim to increase UK public and healthcare professional’s knowledge on AMR by 10%, using 2018 and 2019 baselines.
4. By 2029, we aim to reduce total antibiotic use in human populations by 5% from the 2019 baseline.
5. By 2029, we aim to achieve 70% of total use of antibiotics from the Access category (new UK-AWaRe classification) across the human healthcare system.
International Policy was also discussed in 2025 at the ‘Rising to the Challenge – utilising diagnostic to combat infectious diseases and AMR symposium’ at Les Pensières Center for Global Health.2
Forty-five participants
representing 16 countries and 39 organisations – including policymakers, clinicians, regulators, researchers, and private-sector leaders – explored barriers to the utilisation and valuation of diagnostics across diverse healthcare settings in high-income countries (HICs), middle income countries (MICs) and low-income countries (LICs). Participants prioritised the key areas for action to address undervaluation and
underutilisation of diagnostics: Understanding value: We need to develop a common understanding and nomenclature for the individual, collective, clinical, economic and societal elements of value dimensions of diagnostics. There is insufficient data at present to qualify these. Agreeing and advocating value elements:
A clear next step would be the convening of payers, Health Technology Assessment (HTA) bodies, provider, patients and companies to align the value elements. Piloting and implementing value framework:
Payers and HTA bodies could pilot schemes to inform reimbursement reform, so that the siloed funding of infection testing can be overcome.
Incentivising diagnostics He went on to highlight the subscription model for funding antibiotic development whereby contracts are awarded to companies based on the value of their antibiotics. “It’s a pull incentive to incentivise pharmaceutical companies to stay in the antibiotic space. So, should we have something similar for diagnostic companies?” he questioned. Antibiotic value is evaluated according to the STEDI principles: l Spectrum: The range of pathogens that can be treated with a specific antibiotic.
l Transmission: The benefits of preventing the spread of infection.
l Enablement: Ensuring access to medical care and treatment.
l Diversity: Using a variety of antibiotics to reduce resistance pressure.
l Insurance: The value of having an antibiotic available in case of sudden need.
This framework aims to capture the full societal benefits of antibiotics beyond just their cost- effectiveness. “Other governments around the world are
now copying this process as it is seen as being the way forward,” he commented. Diagnostics require a slightly different incentive framework, and this has led to the development of ‘STRIDES’. The framework incorporates seven AMR-specific value elements: l Spectrum value: Enables use of narrow spectrum antibiotics by identifying specific pathogens and resistance patterns.
l Transmission value: Reducing the spread of resistant pathogens through earlier detection and control.
l Research value: Supporting development of antimicrobials by improving trial recruitment and design.
September 2026 I
www.clinicalservicesjournal.com 27
T -
stock.adobe.com
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85